Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study

Cancer of unknown primary site (CUP) represents up to 5% of all cancer diagnoses and is associated with poor survival. We have performed a prospective multicentre phase 2 trial to evaluate efficacy and toxicity of the combination of gemcitabine (G) and carboplatin (C) for patients with CUP. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Pittman, K B, Olver, I N, Koczwara, B, Kotasek, D, Patterson, W K, Keefe, D M, Karapetis, C S, Parnis, F X, Moldovan, S, Yeend, S J, Price, T J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360587/
https://www.ncbi.nlm.nih.gov/pubmed/17088914
http://dx.doi.org/10.1038/sj.bjc.6603440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360587/
https://www.ncbi.nlm.nih.gov/pubmed/17088914
http://dx.doi.org/10.1038/sj.bjc.6603440

Ejemplares similares